Absence of correlation between risk factors for endometrial cancer and the presence of tamoxifen-associated endometrial polyps in postmenopausal patients with breast cancer

European Journal of Cancer

Volumn 36, Issue SUPPL. 4, 2000, Pages 40-42

  Timmerman, D ^a   Deprest, J ^a   Verbesselt, R ^b   Moerman, P ^b   De Brabanter, J ^c   Vergote, I ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Department of Clinical Pharmacology ^*  (Belgium)

^c Katholieke Universiteit Leuven   (Belgium)

Author keywords

CA125; Endometrial cancer; Endometrium; Oestrogen; Polyps; Tamoxifen

Indexed keywords

CA 125 ANTIGEN; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; UTERUS CANCER;

EID: 0033746516     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(00)00219-7     Document Type: Article

References (9)

1. Tamoxifen and the uterus and endometrium
2. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen
3. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
4. Tamoxifen-induced endometrial polyp
5. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis
6. Risk of endometrial cancer after tamoxifen treatment of breast cancer
7. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in tamoxifen-treated postmenopausal breast cancer patients
8. Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as external carcinogen
9. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients